Qinganxin (Avatrombopag Maleate) – ITP/CLD | HongKong DengYue Medicine

Qinganxin Application Scope

Qinganxin® is indicated for adult patients with thrombocytopenia in the following conditions:

1. Chronic liver disease (CLD)–associated thrombocytopenia
   For adult patients with chronic liver disease who are scheduled to undergo an elective diagnostic procedure or surgery, to increase platelet counts and reduce the risk of bleeding.

2. Chronic primary immune thrombocytopenia (ITP)
   For adult patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or other first-line therapies, as a second-line treatment option.

   

Qinganxin Characteristics

• Ingredients: Avatrombopag Maleate

• Properties:​ Tablet

• Packaging Specification:​ 20 mg per tablet

• Storage:​ Store at room temperature

• Expiry Date: See outer packaging

• Executive Standard: ​See the approved package insert.

• Approval Number: H20203121

• Date of Revision: See the latest approved package insert

• Manufacturer: Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.

Guidelines for the Use of Qinganxin

• Dosage and Administration:

  • Recommended Dose:

    • Chronic Liver Disease–Associated Thrombocytopenia: Administered once daily for 5 consecutive days prior to the scheduled procedure, with dose selection based on baseline platelet count.

    • Chronic Immune Thrombocytopenia (ITP): The usual starting dose is 20 mg once daily. Dose adjustments may be made according to platelet response to maintain a safe platelet count.

  • Administration: Take orally with food to improve drug absorption and consistency.

  • Missed Dose:​ If a dose is missed, take it as soon as remembered on the same day. If it is the next day, skip the missed dose and take the next dose at the regular time. Do not take a double dose.

• Adverse Reactions:

  • Common Adverse Reactions: Headache, fatigue, nausea, abdominal pain, fever, peripheral edema.

  • Serious Adverse Reactions: Signs of thrombosis (e.g., sudden chest pain, shortness of breath, leg pain/swelling), signs of liver problems (e.g., yellowing skin/eyes, dark urine, persistent nausea).

    ​

• Contraindications: Hypersensitivity to avatrombopag or any component of the formulation.

• Precautions:

  • Thrombosis/Risk: May increase the risk of blood clots, especially in patients with pre-existing risk factors.

  • Monitoring: Regular monitoring of platelet counts is required to adjust dosage and avoid excessive platelet increase.

  • Liver Function: Use with caution in patients with severe hepatic impairment (Child-Pugh Class C).
  • Pregnancy & Lactation: Use only if clearly needed; consult a doctor.
  • Drug Interactions: Inform your doctor of all medications you are taking, especially other drugs affecting platelets or blood clotting.

Qinganxin Interactions

• Metal Cations (e.g., iron, calcium, magnesium, aluminum): Unlike some other TPO-RAs (e.g., eltrombopag), avatrombopag does not require separation from meals. rich in these minerals or from supplements/antacids containing them, as it does not chelate polyvalent cations.

• Moderate CYP2C9 and CYP3A4 Inducers/Inhibitors: Potential interactions exist. Inform your doctor if you are taking medications such as rifampin, carbamazepine, fluconazole, etc.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.